Johnson & Johnson secures FDA approval for Darzalex Faspro as the first and only treatment for adults with high-risk smoldering multiple myeloma, supported by Phase III Aquila trial data showing a 51% ...
In today’s Pharmaceutical Executive Daily, we cover Eli Lilly and Novo Nordisk’s plans to bring their leading weight-loss medications to the TrumpRx platform, the State of Texas’ legal move to block ...
The FDA has named six new additions to the Commissioner’s National Priority Voucher (CNPV) program, expanding the initiative to 15 products that address critical public health and national security ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback